CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged
CorMedix (CRMD) reported Q2 revenue of $101.9M, up from $39.7M a year ago, with net income of $26M. Management raised adjusted EBITDA guidance but kept full-year revenue guidance unchanged. DefenCath and the Melinta portfolio drove growth, with new supply agreements signed. The company expects to submit an sNDA for REZZAYO in Q3. Operating expenses increased due to Melinta's costs and R&D spending. Hedge fund ownership rose, while short interest remained high at 22.30%.
How this was made
The 30-second read
Why it matters
The earnings beat and raised EBITDA guidance provide a catalyst for short‑term price movement, while unchanged revenue outlook and litigation risk create uncertainty.
Market read
Earnings release is the primary driver of relevance; the mix of strong profit growth and cautious revenue guidance creates a balanced trade outlook.
What to watch
High short interest and ongoing securities litigation could pressure the stock if results disappoint.
Background
CorMedix reported Q2 2026 results, highlighting a tripling of profits, a new multi‑year dialysis supply contract, and an upcoming sNDA submission for REZZAYO.
Ticker impact
Q2 results show revenue of $101.9M, net income $26M and raised FY adjusted EBITDA guidance while revenue guidance unchanged.
Potential modest rally if investors focus on EBITDA lift; risk of sell‑off if revenue guidance remains flat.
Strong profit growth versus flat top‑line guidance creates mixed signals; short interest (~22% of float) may amplify volatility.
Market effects
Positive earnings may buoy the niche dialysis‑drug sector, but unchanged revenue guidance tempers broader optimism.
U.S. biotech/healthcare market may see modest lift; limited effect on broader indices.
Limited to investors tracking small‑cap biotech and dialysis‑related therapeutics.
Counterpoint
Flat revenue guidance despite profit surge suggests management is cautious; could signal underlying demand weakness.
Key entities
- CompanyCorMedix
NASDAQ‑listed biotech focused on dialysis‑related drugs.
- PartnerMundipharma
Collaborator on REZZAYO sNDA submission.
